ICLR241220P170000
- 3.10
- 0.000.00%
Icon PLC Newsroom
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Baird Upgrades Icon PLC(ICLR.US) to Buy Rating, Raises Target Price to $242
Icon PLC (ICLR) Down 4.1% Since Last Earnings Report: Can It Rebound?
Should You Retain Your Conviction in Icon Plc (ICLR)?
Icon Is Maintained at Neutral by Baird
Icon Price Target Cut to $225.00/Share From $249.00 by Baird
Baird Downgrades Icon PLC(ICLR.US) to Hold Rating, Cuts Target Price to $225
Express News | ICON PLC : Leerink Partners Cuts Target Price to $255 From $270
Pharmacovigilance and Drug Safety Software Market Skyrockets to $359.30 Million by 2031 Dominated by Tech Giants - ArisEurope, ICON Plc and Syneos Health | The Insight Partners
Express News | Shares of IQVIA, Charles River and ICON PLC Down Between 2% and 3%
Express News | Shares of Contract Drug Researchers Fall After Rfk Jr Picked for Top US Health Agency Role
Elliott Investment Management Adds To Southwest, Western Digital, Etsy, Match Group; Trims BILL Holdings, Seadrill, BlackLine, NRG Energy In Q3
Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
ICON Plc to Present at the Jefferies London Healthcare Conference
ICON (NASDAQ:ICLR) Sheds 3.0% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Icon Shares Are Trading Higher. Truist Securities Maintained a Buy Rating on the Stock.
$1000 Invested In This Stock 15 Years Ago Would Be Worth $9,100 Today
Icon Is Maintained at Buy by Truist Securities
ICLR Misses on Q3 Earnings, Lowers 2024 Guidance, Stock Falls
Truist Financial Maintains Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $295